Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 20,000 shares, an increase of 44.9% from the August 15th total of 13,800 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average daily volume of 48,600 shares, the days-to-cover ratio is presently 0.4 days.

Tharimmune Trading Down 0.7 %

Shares of NASDAQ THAR traded down $0.02 during trading on Friday, reaching $2.97. The stock had a trading volume of 21,408 shares, compared to its average volume of 37,550. Tharimmune has a fifty-two week low of $2.54 and a fifty-two week high of $142.50. The business’s 50-day moving average price is $3.15 and its 200-day moving average price is $4.48.

Tharimmune (NASDAQ:THAR) last issued its quarterly earnings results on Friday, August 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).